Literature DB >> 3323861

Use of single radial haemolysis for assessing antibody response to influenza virus vaccines in animals.

T L Smith1, R Jennings, C W Potter.   

Abstract

The value of the single radial haemolysis (SRH) test as a possible replacement for the haemagglutination-inhibition (HAI) test for the estimation of antibodies against influenza was assessed in three animal models. The serum antibody response was measured by both assay systems; correlation of the two tests was assessed using regression analysis. The study showed that when the response to a single immunisation was determined, the ferret model gave satisfactory correlation of SRH and HAI, whilst in the mouse and hamster models poor correlation was observed. Correlation was only improved in the mouse model when an immunisation schedule that mimicked the human situation of a background exposure to different strains of influenza virus was used. Since influenza vaccine efficacy is usually assessed in animals using a single immunisation we suggest that the SRH is not acceptable for use in either hamsters or mice, but is acceptable where the ferret model is involved.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3323861     DOI: 10.1007/BF00194892

Source DB:  PubMed          Journal:  Med Microbiol Immunol        ISSN: 0300-8584            Impact factor:   3.402


  16 in total

Review 1.  Heterogeneous enzyme immunoassay.

Authors:  A J O'Beirne; H R Cooper
Journal:  J Histochem Cytochem       Date:  1979-08       Impact factor: 2.479

2.  Immunoglobulin G, A and M response to influenza vaccination in different age groups: effects of priming and boosting.

Authors:  W E Beyer; J T Van der Logt; R van Beek; N Masurel
Journal:  J Hyg (Lond)       Date:  1986-06

3.  The use of the single radial haemolysis test for assessing antibody response and protective antibody levels in an influenza B vaccine study.

Authors:  A C Goodeve; R Jennings; C W Potter
Journal:  J Biol Stand       Date:  1983-10

4.  The hamster as an experimental animal for the study of influenza. I. The role of antibody in protection.

Authors:  R Jennings; M D Denton; C W Potter
Journal:  Med Microbiol Immunol       Date:  1976-12-01       Impact factor: 3.402

5.  Use of a zwitterionic detergent for the preparation of an influenza virus vaccine: 2. Immunogenicity of Empigen-treated virus in animals.

Authors:  F A Mukhlis; C R Crawford; R Jennings; C W Potter
Journal:  Vaccine       Date:  1984-09       Impact factor: 3.641

6.  Inactivated influenza virus vaccines in man: a comparative study of subunit and split vaccines using two methods for assessment of antibody responses.

Authors:  R Jennings; T L Smith; R C Spencer; A M Mellersh; D Edey; P Fenton; C W Potter
Journal:  Vaccine       Date:  1984-03       Impact factor: 3.641

7.  Comparison of haemagglutination-inhibition and single-radial-haemolysis techniques for detection of antibodies to influenza B virus.

Authors:  P Chakraverty
Journal:  Arch Virol       Date:  1980       Impact factor: 2.574

8.  Immunoglobulin M and G antibody response to type- and subtype-specific antigens after primary and secondary exposures of mice to influenza A viruses.

Authors:  N J Gonchoroff; A P Kendal; D J Phillips; C B Reimer
Journal:  Infect Immun       Date:  1982-05       Impact factor: 3.441

9.  Reassortants of influenza B viruses for use in vaccines: an evaluation.

Authors:  A C Goodeve; R Jennings; C W Potter
Journal:  Arch Virol       Date:  1985       Impact factor: 2.574

10.  Quantitation and analysis of the specificity of post-immunization antibodies to influenza B viruses using single radial haemolysis.

Authors:  J S Oxford; R Yetts; G C Schild
Journal:  J Hyg (Lond)       Date:  1982-04
View more
  1 in total

1.  Antigen-specific tumor vaccine efficacy in vivo against prostate cancer with low class I MHC requires competent class II MHC.

Authors:  Yilin C Neeley; Kevin T McDonagh; Willem W Overwijk; Nicholas P Restifo; Martin G Sanda
Journal:  Prostate       Date:  2002-11-01       Impact factor: 4.104

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.